Healius share price on watch after trading update

The Healius Ltd (ASX: HLS) share price is on watch as the Aussie healthcare company provided a trading update at its AGM today.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Healius Ltd (ASX: HLS) share price is on watch this morning after a trading update provided at the company's annual general meeting (AGM).

a woman

What could move the Healius share price?

While shareholders are waiting to hear from management at the AGM, all eyes will be on the company's trading and management update released this morning.

Healius announced underlying net profit after tax (NPAT) for FY20 is expected to be between $94 million and $102 million, which could see the Healius share price move today.

At the top end of that range, this would represent a 9.4% increase on the prior corresponding period (pcp) as anticipated in the company's 16 August update. Healius would then have delivered in line with the seasonally adjusted run rate from 2H 2019.

The Aussie healthcare company also confirmed a raft of management changes in today's announcement. Scott Beattie will be taking over as CEO of the group's Medical Centres business. These changes all form part of Healius' organisational re-design, which was announced earlier this year.

What else did Healius announce?

Chairman Rob Hubbard noted FY19 was a big year for the Aussie healthcare group. The company rebranded as Healius during the year and rejected a takeover bid from its major shareholder, Jangho, due to share price and conditionality.

In terms of financials, Healius delivered revenue up 6% on pcp to $1.8 billion with underlying NPAT up 6.5% to $93 million as the Healius share price climbed higher in 2019.

Pathology was the company's largest division, with about 60% of the group's profit on the back of a 2H 2019 turnaround. Healius' Medical Centres division grew revenue and EBIT by 13% and 19%, respectively, and the Imaging division delivered a third successive year of double-digit growth.

Mr. Hubbard said FY20 will be the peak year of adjustments to the company's reported earnings. 

Capital expenditure remained higher in FY19, mostly due to strategic investments such as its Montserrat Day Hospitals acquisition.

The Healius share price is up 27.87% to $3.12 per share, prior to this morning's open.

Motley Fool contributor Kenneth Hall has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Lab worker puts hands in the air and dances around.
Healthcare Shares

CSL shares look primed to take off — Here's why

Business remains robust and brokers see ASX stock soaring up to 100%.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

ASX 300 healthcare stock outperforming today on 'strategic' leadership news

The ASX healthcare stock announced the outcome of its CEO recruitment drive this morning.

Read more »

Cropped shot of a young female scientist working on her computer in the laboratory.
Healthcare Shares

Could Telix shares be a millionaire-maker stock?

Telix looks a compelling growth story, with brokers eyeing more than 150% upside.

Read more »

A child covering his eyes hiding from a toy bear.
Healthcare Shares

Down 20% in 2026, is now the time to buy CSL shares?

CSL shares hit a new multi-year low as the 2026 decline deepens.

Read more »

Scientists in white coats look disappointed.
Healthcare Shares

Down 87% since Thursday, why is this ASX 300 healthcare stock sliding again today?

The ASX healthcare share has plunged more than 87% in five trading days.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Which ASX biotech's shares have jumped more than 10% on positive clinical trial news?

A potential cancer treatment is progressing.

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

3 ASX healthcare stocks tipped to soar over 100% higher this year

These ASX shares are on my radar this week.

Read more »

Scientists working in the laboratory and examining results.
Opinions

3 reasons to buy CSL shares today

The ASX biotech company has great growth potential this year.

Read more »